{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:06:31Z","timestamp":1786687591059,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jgo.2026.103024","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:55:43Z","timestamp":1781729743000},"page":"103024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma in the post-cBTKi setting"],"prefix":"10.1016","volume":"17","author":[{"given":"Paolo","family":"Ghia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Ferrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"de la Cruz Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Versha","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Namburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalin","family":"Payakachat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naleen Raj","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Abada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9ly","family":"Loubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Creel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching Ching","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jgo.2026.103024_bb0005","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III trial of Pirtobrutinib versus Idelalisib\/rituximab or Bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor-Pretreated chronic lymphocytic Leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jgo.2026.103024_bb0010","first-page":"279","article-title":"The clinical and epidemiological burden of chronic lymphocytic leukaemia","volume":"13","author":"Redaelli","year":"2004","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.jgo.2026.103024_bb0015","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on Core patient-reported outcomes in Cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jgo.2026.103024_bb0020","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2021-147885","article-title":"Real-world evaluation of the treatment landscape for chronic lymphocytic Leukemia","volume":"138","author":"Smith","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2026.103024_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02841860260088764","article-title":"Quality-of-life assessment in oncology. Achievements and challenges","volume":"41","author":"Sprangers","year":"2002","journal-title":"Acta Oncol."},{"key":"10.1016\/j.jgo.2026.103024_bb0030","first-page":"1089","article-title":"The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year","volume":"22","author":"Deshields","year":"2014","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2026.103024_bb0035","first-page":"62","article-title":"Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2026.103024_bb0040","series-title":"Pirtobrutinib in covalent BTK-inhibitor pre-treated CLL\/SLL","author":"Mato","year":"2023"},{"key":"10.1016\/j.jgo.2026.103024_bb0045","series-title":"Jaypirca [Prescribing Information]","year":"2023"},{"key":"10.1016\/j.jgo.2026.103024_bb0050","series-title":"in Agency EM (ed)","author":"Jaypirca EPAR (EMEA\/H\/C\/005863)","year":"2025"},{"key":"10.1016\/j.jgo.2026.103024_bb0055","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2026.103024_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41687-024-00683-2","article-title":"Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library","volume":"8","author":"Markowitz","year":"2024","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jgo.2026.103024_bb0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jgo.2026.103024_bb0070","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of Cancer quality of life questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jgo.2026.103024_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of Cancer quality of life questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jgo.2026.103024_bb0080","series-title":"Guidelines for selecting the covariance structure in mixed model analysis","author":"Kincaid","year":"2005"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826001785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826001785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:29:35Z","timestamp":1785907775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826001785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1879406826001785"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.103024","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma in the post-cBTKi setting","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.103024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103024"}}